Dr. Clifford A. Hudis on Why Resistance to HER-2 Therapies Needs to be Further Researched
Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, talks about the vague understanding medical professional currently have of HER-2 breast cancer and its resistance to certain therapies.
Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, talks about the vague understanding medical professionals currently have of HER-2 breast cancer and its resistance to certain therapies.
Hudis explains that while some studies have suggested that patients would be better off switching therapies due to breast cancer not responding to the treatment, further studies have shown that the benefits of staying with those therapies may outweigh the negative effects. Hudis says that this is a challenge to the idea of drug resistance itself.
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
